News & Updates

First-line maintenance therapy with niraparib at an individualized starting dose (ISD) improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer, according to results of the phase III PRIME study presented at SGO 2022.

Daily use of aspirin reduces the risk of incident hepatocellular carcinoma (HCC), while the combination of daily aspirin use and statin results in a lower incidence of HCC, which suggests a beneficial interaction, according to a study. In addition, no excess oesophageal variceal haemorrhage (VH) is seen among daily aspirin users compared with nonusers.

Breast cancer patients who take statins see a sharp decline in the risk of tumour recurrence, according to a recent Singapore study. This protective effect seems to be stronger in ER+ and HER2- malignancies.

Treatment with a guideline-based thromboprophylaxis in multiple myeloma patients and the addition of pharmacy oversight to risk assessment can help reduce the risk of venous thromboembolism (VTE), suggests a recent study.